ModernaNASDAQ: MRNA

In the latest trading session, Moderna (MRNA) finished at $55.22, showing an increase of 0.77% compared to the day before.

CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) has been named one of the best employers in the global biopharmaceutical sector in the 2024 Top Employers Survey by Science and Science Careers for the tenth year in a row. The company was acknowledged for its dedication to ongoing innovation, respect for its employees, and commitment to social responsibility.

Moderna, Inc.'s stock price has dropped because of lower demand for COVID-19 vaccines, but its varied assets can help it grow in the future. The company is concentrating on vaccines for respiratory illnesses like RSV, flu, and COVID-19 variants to maintain and increase its income. Even with high research and development costs and notable losses, Moderna's projects in areas like cancer treatment and other vaccines have great long-term promise.

Moderna (MRNA) closed at $53.80 on the most recent trading day, showing a decrease of 0.55% from its previous closing price.

Scientists are working on creating a vaccine that they believe could be the first effective treatment for the highly contagious and hard-to-treat Clostridioides difficile bacteria. They are using the same technology that was used in the groundbreaking mRNA vaccines for the coronavirus responsible for COVID-19.

CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA) has announced that it will hold a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024. During this event, the company will share its financial results for the third quarter of 2024 and give a corporate update.

MRNA's stock has been falling since the company reduced its long-term financial expectations. Additionally, it has postponed its breakeven target by two more years, now aiming for 2028.

On Tuesday, GlaxoSmithKline filed a lawsuit against Moderna in a federal court in Delaware, claiming that Moderna infringed on GSK's patent rights related to messenger RNA (mRNA) technology used in its successful COVID-19 vaccine, Spikevax.

Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has released the "mRNA Therapeutics Market Report 2024." The market for mRNA therapeutics has been increasing consistently, projected to rise from $33.5 billion in 2023 to $34.76 billion in 2024, with a compound annual growth rate (CAGR) of 3.8%. It is anticipated that the market will continue to grow, reaching $40.69 billion by 2028 at a CAGR of 4%.